0000000000345293

AUTHOR

Maria Rinzivillo

showing 3 related works from this author

Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neur…

2020

Introduction The organization of the healthcare system has significantly changed after the recent COVID-19 outbreak, with a negative impact on the management of oncological patients. The present survey reports data collected by the Italian Association for Neuroendocrine Tumors on the management of patients with neuroendocrine neoplasia (NEN) during the pandemic dissemination. Methods A survey with 57 questions was sent to NEN-dedicated Italian centers regarding the management of patients in the period March 9, 2020, to May 9, 2020 Results The main modification in the centers’ activity consisted of decreases in newly diagnosed NEN patients (− 76.8%), decreases in performed surgical procedure…

AdultMalePediatricsmedicine.medical_specialtyEndocrinology Diabetes and MetabolismAntineoplastic Agents030209 endocrinology & metabolismNeuroendocrine tumorsMedical OncologyNO03 medical and health sciencesPatient safety0302 clinical medicineEndocrinologyAmbulatory careNeuroendocrine tumorSurveys and QuestionnairesEpidemiologyPandemicHumansMedicineLS4_3PandemicsPatient Care TeamPandemicbusiness.industryCOVID-19Multidisciplinary teamContinuity of Patient Caremedicine.diseaseManagementClinical trialItalyCOVID-19; management; multidisciplinary team; neuroendocrine tumors; pandemic; peptide receptors radionuclide therapy; SARS-CoV2030220 oncology & carcinogenesisRadionuclide therapySARS-CoV2s COVID-19 SARS-CoV2 Pandemic Neuroendocrine tumors Multidisciplinary team Management Peptide receptors radionuclide therapyPeptide receptors radionuclide therapyOriginal ArticleFemaleneuroendocrine tumorsbusinessHealth care quality
researchProduct

Safety of high doses of somatostatin analogs in well differentiated NENs in elderly

2019

Abstract Background Neuroendocrine neoplasms (NENs) are a group of heterogeneous neoplasms which can be treated with different therapies: in well differentiated (WD) NENs analogs of somatostatin (SSA) can be used considering their proved antineoplastic and antisecretory effects. This is a multicenter study to investigate the safety of high doses (HDD) analogs of somatostatin (SSA) in WD NENs with particular attention for patients over 70 years of age. Methods We collected clinical data from 13 Italian NENs dedicated Units. Patients with WD NENs, in progression on previous treatments, included SSA, and subsequently treated with HDD-SSA, were considered. Results 170 pts were included: 61.76% …

medicine.medical_specialtyGastrinomabusiness.industryHematologyNeuroendocrine tumorsmedicine.diseaseGastroenterologyZollinger-Ellison syndromeSteatorrheaOncologyInternal medicineCholecystitisMedicinemedicine.symptombusinessInsulinomaCarcinoid syndromeMalignant Carcinoid SyndromeAnnals of Oncology
researchProduct

Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study.

2018

Abstract Introduction Besides data reported in a Phase-III trial, data on sunitinib in pancreatic Neuroendocrine Tumors (panNETs) are scanty. Aim To evaluate sunitinib efficacy and tolerability in panNETs patients treated in a real-world setting. Patients and methods Retrospective analysis of progressive panNETs treated with sunitinib. Efficacy was assessed by evaluating progression-free survival, overall survival, and disease control (DC) rate (stable disease (SD) + partial response + complete response). Data are reported as median (25th–75th IQR). Results Eighty patients were included. Overall, 71.1% had NET G2, 26.3% had NET G1, and 2.6% had NET G3 neoplasms. A total of 53 patients (66.3…

0301 basic medicineIndolesEndocrinology Diabetes and MetabolismNeuroendocrine tumorsPyrroleGastroenterologyTarget therapyEfficacyAntineoplastic Agent0302 clinical medicineEndocrinologyRetrospective StudieSunitinibPancreadiabetes and metabolismSunitinibGastroenterologyPancreatic NeoplasmMiddle AgedDiabetes and MetabolismNeuroendocrine TumorsTreatment OutcomeTolerabilityNeuroendocrine tumors; Pancreas; Progressive disease; Sunitinib; Target therapy; Endocrinology Diabetes and Metabolism; Hepatology; EndocrinologyItaly030220 oncology & carcinogenesisNeuroendocrine tumorsmedicine.drugHumanAdultmedicine.medical_specialtyAntineoplastic AgentsNeutropenia03 medical and health sciencesNeuroendocrine tumorInternal medicinemedicineHumansPyrrolesProgression-free survivalPancreasCancer stagingAgedRetrospective StudiesHepatologybusiness.industryProgressive diseasemedicine.diseasePancreatic Neoplasms030104 developmental biologyNeuroendocrine tumors; pancreas; progressive disease; Sunitinib; target therapy; endocrinology; diabetes and metabolism; hepatology; endocrinologyIndolebusinessProgressive diseasePancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
researchProduct